SCHEMBL10027187

SCHEMBL10027187

CC(C)c1cnc2c(O)cccn2c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.43
▸ ALDH1A1 P00352 4/20 0.43
▸ KDM4E B2RXH2 3/20 0.43
▸ GAA P10253 2/20 0.43
▸ GLA P06280 1/20 0.43
▸ MPI P34949 1/20 0.43
▸ GABRA1 P14867 1/20 0.39
▸ GABRB2 P47870 1/20 0.39
▸ KDM5A P29375 1/20 0.38
▸ ANPEP P15144 1/20 0.35
▸ DPP4 P27487 1/20 0.35
▸ TP53 P04637 6/20 0.35
▸ MAPT P10636 4/20 0.35
▸ SMN1; SMN2 Q16637 3/20 0.35
▸ HPGD P15428 3/20 0.33
▸ MDM4 O15151 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ TYR P14679 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13313511 0.81 ALDH1A1 (0.49) LMNAALDH1A1KDM4EGAAGLA
SCHEMBL23696295 0.80 LMNA (0.40) LMNAALDH1A1KDM4EGAAGLA
SCHEMBL10027225 0.78 LMNA (0.43) LMNAALDH1A1KDM4EGAAGLA
SCHEMBL13313514 0.78 KDM4E (0.42) LMNAALDH1A1KDM4EGAAGLA
SCHEMBL13348692 0.77 ALDH1A1 (0.42) LMNAALDH1A1KDM4EGAAGLA
SCHEMBL19365017 0.77 KDM5A (0.37) LMNAALDH1A1KDM4EGAAGLA
SCHEMBL19361112 0.76 TP53 (0.39) LMNAALDH1A1TP53MAPTSMN1; SMN2
SCHEMBL17802285 0.76 KDM5A (0.36) LMNAALDH1A1KDM4EGAAGABRA1
SCHEMBL10027232 0.76 KDM5A (0.36) LMNAALDH1A1KDM4EGAAGABRA1
SCHEMBL13313516 0.75 KDM4E (0.40) LMNAALDH1A1KDM4EGAAGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3227292-B1 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS ALTERITY THERAPEUTICS LTD (AU) 2022-03-09 — — EP disclosed
US-20210230159-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2021-07-29 — — US disclosed
US-11008319-B2 4H-pyrido[1,2-a]pyrimidin-4-one compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2021-05-18 — — US disclosed
US-20200317670-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2020-10-08 — — US disclosed
US-10738050-B2 4H-pyrido[1,2-A]pyrimidin-4-one compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2020-08-11 — — US disclosed
US-20190352301-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2019-11-21 — — US disclosed
US-10287285-B2 4H-pyrido[1,2-A]pyrimidin-4-one compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2019-05-14 — — US disclosed
US-20170267676-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2017-09-21 — — US disclosed
US-20170267676-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2017-09-21 — — US disclosed
WO-2016086261-A1 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2016-06-09 — — WO disclosed
US-8163760-B2 Use of pyridopyrimidine compounds in the treatment of gliomas PRANA BIOTECHNOLOGY LIMITED (AU) 2012-04-24 — — US disclosed
US-8163760-B2 Use of pyridopyrimidine compounds in the treatment of gliomas PRANA BIOTECHNOLOGY LIMITED (AU) 2012-04-24 — — US disclosed
US-20110071167-A1 METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) PRANA BIOTECHNOLOGY LIMITED (AU) 2011-03-24 — — US disclosed
US-20110071167-A1 METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) PRANA BIOTECHNOLOGY LIMITED (AU) 2011-03-24 — — US disclosed
US-20100144693-A1 METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) PRANA BIOTECHNOLOGY LIMITED (AU) 2010-06-10 — — US disclosed
US-20100144693-A1 METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) PRANA BIOTECHNOLOGY LIMITED (AU) 2010-06-10 — — US disclosed
US-20100069393-A1 METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME PRANA BIOTECHNOLOGY LIMITED (AU) 2010-03-18 — — US disclosed
US-20100069393-A1 METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME PRANA BIOTECHNOLOGY LIMITED (AU) 2010-03-18 — — US disclosed
WO-2007147217-A1 METHOD OF TREATMENT OF GLIOMA BRAIN TUMOUR PRANA BIOTECHNOLOGY LIMITED (AU) 2007-12-27 — — WO disclosed
WO-2007118276-A1 METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION(AMD) PRANA BIOTECHNOLOGY LTD (AU) 2007-10-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738050-B2 4H-pyrido[1,2-A]pyrimidin-4-one compounds PSEN2, PSEN1, PNPO LMNA 1246/4885ALDH1A1 299/4885KDM4E 2827/4885
US-20100069393-A1 METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME MGMT, DHFR, IDH2 LMNA 2250/4885ALDH1A1 1278/4885KDM4E 2823/4885
US-20200317670-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PSEN2, PSEN1, PNPO LMNA 1246/4885ALDH1A1 299/4885KDM4E 2827/4885
US-10287285-B2 4H-pyrido[1,2-A]pyrimidin-4-one compounds PSEN2, PSEN1, PNPO LMNA 1246/4885ALDH1A1 299/4885KDM4E 2827/4885
US-11008319-B2 4H-pyrido[1,2-a]pyrimidin-4-one compounds PSEN2, PSEN1, PNPO LMNA 1246/4885ALDH1A1 299/4885KDM4E 2827/4885
US-20190352301-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PSEN2, PSEN1, PNPO LMNA 1246/4885ALDH1A1 299/4885KDM4E 2827/4885
US-20100144693-A1 METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) ALDH1A2, AGER, PDE6C LMNA 400/4885ALDH1A1 238/4885KDM4E 4624/4885
US-20210230159-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PSEN2, PSEN1, PNPO LMNA 1246/4885ALDH1A1 299/4885KDM4E 2827/4885
US-20170267676-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PSEN2, PSEN1, PNPO LMNA 1246/4885ALDH1A1 299/4885KDM4E 2827/4885
US-20110071167-A1 METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) ALDH1A2, AGER, PDE6C LMNA 400/4885ALDH1A1 238/4885KDM4E 4624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback